ejpmr, 2022,9(9), 103-109

SJIF Impact Factor 6.222

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

Review Article

ISSN 2394-3211

EJPMR

NEPHROLITHIASIS- A REVIEW

Ayush Singh*, Priya, Rahul, Riya Sehgal, Rupinder Kaur, Sachit Sharma and Sukhmanbir Singh

Department of Pharmacy, Global Group of Institutes, Amritsar, Punjab, India-143501.

***Corresponding Author: Ayush Singh**

Department of Pharmacy, Global Group of Institutes, Amritsar, Punjab, India-143501.

Article Received on 23/06/2022 **Article Revised on 13/07/2022** **Article Accepted on 03/08/2022**

ABSTRACT

Nephrolithiasis often initiate renal colic and a common problem across the globe. Producing stones in the renal region, bladder, and urethra lead to this chronic disorder i.e. nephrolithiasis. Stones present in the renal or urinary regions are mineral stones that are present in the renal calyces and renal pelvis generally seen an appended to the renal papillae. These stones that impede the renal pelvis those deal with unbearable, blinking pain that goes from the flank to the groin or to the genital area. Maximum amount of kidney stones are produced from the Calcium phosphate generally known as Randall's plaques. There are various types of renal calculi that are composed of calcium (Ca^{2++}). This is recognized as systemic pathology that may lead to end stage renal disease. This review is an effort to revitalize the concept of nephrolithiasis, basically work on its etiological parameters, pathophysiological pathways. This article also put light on medications that are accessible and utilizes in the therapeutics of nephrolithiasis and along with medications this review also discuss a part unique contemplations in pregnant women of nephrolithiasis.

KEYWORDS: Kidney Stone, Nephrolithiasis, Kidney, crystal, hypercalciuria, calcium, urinary tract, drugs.

INTRODUCTION

Nephrolithiasis, is the normal condition influencing the urinary framework that chiefly held up in the kidney.[1] It is generally called as kidney stone that are arises due to crystalline solidification going from the kidney via genitourinary framework.[2,3] It corresponds with an expanded danger of ongoing kidney sicknesses, end-stage renal disappointment, CVS infections, diabetes, and hypertension.[4] Around 80% of Ca^{2++} stones are shaped in numerous patients with nephrolithiasis, the majority of which are made basically out of calcium oxalate or calcium phosphate. Several other types of painful stones namely such as uric corrosive, struvite (magnesium ammonium phosphate), and cystine stones. This is because of Low liquid admission history of diabetes,[5] corpulence, gout, and hypertension and several metabolic ailments.[6] Kidney stones have been related with an expanded danger of ongoing kidney illnesses,[7] end-stage renal disappointment,[8,9] cardiovascular diseases,[10] obesity,[11] diabetes, and hypertension. There are various mechanisms to prevent neprolithiasis prevention and medical treatment.[12] This is elaborated as nephrolithiasis is the primitive disease that are directly accompanying with the metabolic disorder. Nephrolithiasis is liable for 2 to3% of end-stage renal cases in the event that it is related with nephrocalcinosis.[13] There are several allopathic medications that are utilizes in the therapeutics of kidney stone management are NSAIDS, Alkali citrates, Xanthine oxidase antagonist i.e. Allopurinol Bisphosphonates, and thiazide diuretics. There is an extraordinary guarantee for the improvement of novel medications for the treatment of nephrolithiasis because of its adequacy and security.

Kinds of kidney stones

There are basically four major kind of kidney stone present in the kidney that are given below; Calcium (75 to 85%), struvite (2 to 15%), uric corrosive (6 to10%) and stones of cystine (1 to 2%).[14]

Calcium stones

The stones of calcium oxalate, calcium urate and calcium phosphate are related with hypercalciuria which brought about by hyperparathyroidism. Individuals related with illness, expanded calcium assimilation from the stomach causes renal calcium or phosphate spill, hyperuricosuria, hyperoxaluria, hypocitraturia and hypomagnesuria created.[15]

Struvite stones

These stones are composed of magnesium ammonium phosphate i.e. $NH_4MgPO_4 \cdot 6H_2O$ stones which develop to fill the gathering framework. This stage is created because of constant urinary diseases which brought about by Gram-negative urea-dividing bars including Proteus, Pseudomonas and Klebsiella species.[16]

Uric corrosive stones

The development of uric corrosive stones rely on high purine consumption medications or high cell turn over which are generally found in patients with gout. These are formed in slightly acidic urine at the pH 5.5. They are noticeable in nature and generally radiolucent on X-beam film.[17]

Cystine stones

These stone formed because of cystinuria in which the reingestion of cystine in the renal tubule is retard. These stones could hard to track down on X-beams in view of high sulfur content. In drug-incited stones, a few medications can take an interest in the development of renal stones.[18]

Other; Drug-initiated stones

Some medications are likewise taking part in the development of renal stones which can be utilized for another sickness. Few antiviral medication possess this disorder; indinavir, atazanavir, guaifenesin, triamterene, silicate (stomach settling agents) and sulfa drugs. These stones are uncommon and are constantly seen on X-Rays (radiolucent).[19]

Development of calcium oxalate renal stone

Development of calculi is due to the dilation of urinary supersaturation along with the conformational growth of translucent particles. As per the collaborative view of solid particles, these particles take their own shape in the urinary tract.[20] Notwithstanding, when strong particles are held inside the kidney, they can develop to turn out to be standard size stones.[21] Precious stones can be held at many locales in the kidneys and go through the size improving course of development and collection. With the goal for stones to be shaped, in addition to the fact that crystals need to be held inside the kidney and crystals produces ulceration in the surface of papillary. It is believed that renal cylindrical injury assumes a significant part now. Renal rounded injury advances crystal maintenance and the improvement of a stone nidus on the renal papillary surface.[22] Furthermore, kidney rounded injury enhances crystal nucleation at low supersaturation.[23] Precious stone cell communication is the subsequent stage, and is likewise advanced by renal cylindrical injury. Since crystal development is a typical peculiarity in human urine and crystalluria essentially is innocuous, strange maintenance of framed particles should happen when kidney stones structure. Accordingly, crystal cell collaborations might be profoundly applicable. The crystals that are disguised in the interstitium go through development and total, and form into renal stones. Every one of these cycles is portrayed exhaustively underneath.

Symptoms

Hydronephrosis causes a ton of agony in the kidneys and regarded as the main symptom of nephrolithiasis. Normal side effects of kidney stones are confirmed by an intense, unexpected, sharp and wavy aggravation toward the back and its entire side, which can be moved to the lower mid-region or genital space.[24] A portion of the ladies patients say the aggravation which is more terrible than labor work torments. It makes a circumstance of come and goes torment with distress. The sign and manifestations are sensation of urinary urgency.[25] Burning inclination at urinary. The shade of the urine will be dim or red because of blood particles of RBCs. At times the shade of the blood is extremely less that isn't seen by unaided eyes. Sensation of queasiness and retching. Male patients feel severe mental and physical suffering at the tip of their penis.[26]

Etiology

Renal stones are crystal like mineral declarations that construction from small crystal on the Henle, distal tubules. This is generally due to raised levels of urinary solutes, similar to calcium, uric destructive, oxalate, and sodium, similarly as decreased levels of stone inhibitors, for instance, citrate and magnesium.[27]

Low urinary volume and peculiarly low or high urinary pH in like manner add to this cycle. These can provoke urine supersaturation with stone-forming salts and coming about stone improvement.[28] Generally, Supersaturation of urine depends upon urine pH, ionic strength, solute obsession, and solute compound affiliation. The higher the gathering of two particles, the more likely they are to rush out of plan and design valuable stones. As molecule centers increase, their thing to do shows up at the dissolvability thing. Obsessions over this point can begin valuable stone turn of events. At whatever point pearls are molded, they either drop with the urine or become held in the kidney, where they can create and stones can outline. In urine, regardless, when the intermingling of calcium oxalate outperforms the dissolvability thing, crystallization may not occur taking into account a version from urinary inhibitors.

There are various kinds of kidney stones present in the renal region of human body. About 80% of calculi are comprises of calcium oxalate [CaC_2O_4] or calcium phosphate [$Ca_3(PO_4)_2$]. These patients possess hypocitraturia.[30,31] Except these stones, several other stones are also present such as uric corrosive, struvite, and cystine in the amount of 9%, 10% and 1% respectively. Cystine stones are generally rare than stones made out of calcium.[29] Presence of these stones in the human renal region are due to several factors such as family background of stones, ecological elements, prescriptions, and the patient's clinical history.

High intake of salt lead to this disorder.[29] An earlier close to home and family background of kidney stones will build the patient's danger of creating ensuing stones generously. Strategies, for example, gastric bypass surgery and sleeve gastrectomy have shown a three-overlap expansion in calcium oxalate stone development optional to the malabsorptive post-careful state, bringing about expanded urinary oxalate levels, diminished

creation of urine, and diminished urine citrate.[32] The presence of ailments, for example, ongoing kidney sickness, hypertension, gout, diabetes mellitus, hyperlipidemia, stoutness, endocrine, and malignancies increment the danger of the improvement of kidney stones. Heftiness, hyperlipidemia, and type 2 diabetes mellitus have a solid relationship with calcium oxalate and uric corrosive stones. Patients with narratives of hyperlipidemia, hypertension, and type 2 diabetes mellitus frequently have slims down that are high in creature determined proteins, salt, and sugar, setting them at higher danger for stone crystals. Insulin opposition in weight and type 2 diabetes mellitus advances metabolic changes that expansion the danger of stone development auxiliary to expanded urinary calcium and uric corrosive discharge. A new report assessing 4500 patients with a background marked by kidney stones and insulin obstruction showed expanded urinary pH and diminished urinary corrosive discharge, advancing nephrolithiasis/ urolithiasis. An imminent, enormous review followed members throughout the long term and evaluated beginning weight, weight gain, dietary openness, BMI, and abdomen circuit and firmly showed that while expanded BMI raises the danger of suggestive stone arran crystalent, expanded load because of adiposity in adulthood assumes an exceptionally key part.[33]

Drug-prompted urolithiasis is uncommon and just tradeoffs 2% of stones. Proteases inhibitors stones are inadequately imagined on unenhanced CT examine and are thick in material, making them regularly unsusceptible to lithotripsy.[34] There are several anti-HIV drugs that are based upon the urolithiasis.[35] They regularly cause a high-grade urinary deterrent requiring ureteral stenting. Ceftriaxone has been displayed to build the danger of stone development in patients who are on long haul treatment.[36,37] Patient with uric corrosive stone, basically connected with urine with low pH that will possess uric stones growth and precipitation easily at the pH of 5.5. Gout, certain neoplastic disorder, and persistent loose bowels are also additionally connected with uric corrosive stone growth.[38] Cystine stones are uncommon stones. They regularly present in youth or puberty, however a few cases have even been displayed in newborn children.[39] Lack of hydration from low liquid admission is a central point in stone formation.[40,41] Individuals residing in warm environments are at higher danger because of expanded liquid loss.[42] Obesity, idleness, and stationary ways of life are other driving danger factors.[43] High dietary admission of creature protein,[44] sodium, sugars including honey, refined sugars, fructose and high fructose corn syrup,[45,46] and over the top utilization of natural product juices might build the danger of kidney stone crystal because of expanded uric corrosive discharge and raised urinary oxalate levels (while tea, espresso, wine and lager might diminish the risk).[41,42] Kidney stones can result from a hidden metabolic condition, for example, distal renal rounded acidosis,[45] crohn's disease,[46,47] hyperparathyroidism,[48] essential hyperoxaluria,[43] or medullary wipe kidney. 3–20% of individuals who structure kidney stones have medullary wipe kidney.[49,50]

This disease is generally normal in those patients who are already dealing with Crohn's disease;[51] Crohn's sickness is related with hyperoxaluria and malabsorption of magnesium.[45] An individual with intermittent kidney stones might be evaluated for such problems. This is regularly finished with a 24-hour urine assortment. The urine is investigated for highlights that advance stone formation.[52]

Pathophysiology

Initiation and development of crystal's growth in supersaturated urine will attached to the urothelium layer. Hence, creating the nidus for subsequent kidney crystal development. Calcium oxalate stones develop on Randall's plaques which are comprises of calcium phosphate or hydroxyapatite crystals. Calcium oxalate deposition is basically occurring at the surface of urothelium. Several theories such as fixed particle theory and free particle theory are also focus on the role of cell surface molecules which favour or inhibit the adhesion of crystal.[53,54] Urothelial injury and repair after a stone episode may increase surface expression of these molecules to favor further crystal adhesion.[55] Due to residual nucleus, new stones may upgrade of molecule that possess crystal adhesion.[56] Prevention of kidney stone focuses on ameliorating the risk factors for crystal formation. Renal stone formation progresses in successive steps.[57]

Nucleation: Due to alteration of phase, dissolved salts in the fluids are comes into solid existence that basically depends upon the urine's saturation. At the point of supersaturation, salt dissolved in the urine even its concentration exceeds its solubility and this is considered as metastable. Upper limit of metastability is recognized when there is the settling of soluble salts in the urine above its supersaturation point.[58] This process may be due to mixing of same dissolved salts, when crystal precipitation happens spontaneously in a supersaturated urine or heterogeneous when it occurs at lower degrees of saturation in the presence of nucleating agents (i.e. cells, crystals, urinary proteins or components of the epithelial cells); Retention of the initial nucleus in sites of the urothelium; Crystal's growth; Crystal's aggregation.[59] Pathogenetic mechanisms of lithogenesis are based upon free particle theory, fixed particle theory, Interstitial apatite plaque.

Clinical clues of urinary calculi with respect to their diagnoses

These are enlisted underneath in the table no.1 that legitimizes one of the perspective clues behind urinary calculi.[60,61]

Table 1: Clinical clues with respect to their diagnose.

S.NO.	Clinical Clues	Diagnoses
1.	**Dysuria**	Urinary Tract Infection, Pelvic Pain Syndrome, Interstitial Cystitis, inflammation in vagina, prostatitis, Benign Prostatic Hyperplasia, Hyperglycemic, Urinary Bladder Spasms
2.	**Chills**	
3.	**Pyrexia**	Nonspecific inflammatory responses
4.	**Hematuria**	Uroepithelial carcinoma, prostatic carcinoma, renal calculi, glomerulopathy, UTI
5.	**Nausea & vomiting**	Non specific pain outcome
6.	**Tenderness abdomen pain**	Renal calculi, GIT disorder
7.	**Flank**	Musculoskeletal inflammation, pyelonephritis
8.	**Groin**	Pelvic inflammatory responses , pelvic pain syndrome, urethritis

Allopathic Medications that are use in the management of nephrolithiasis

There are several drugs that are utilized in the therapeutics of nephrolithiasis that are enlisted in the table no. 2 with appropriate example.

Table 2: Drugs for Nephrolithiasis with respect to appropriate example.

S.NO.	Drug	Example	Reference
9.	**Thiazide**	Hydrochlorothiazide	[62]
10.	**Alkali citrate salts**	Potassium citrate	[63]
11.	**Xanthine oxidase inhibitors**	Allopurinol	[64]
12.	**Bisphosphonates**	Risedronate	[65]
13.	**Potassium sparing diuretics**	Triamterene	[66]
14.	**Antibiotics**	Antimicrobial antibiotics such as sulfamethoxazole, ciprofloxacin, trimethoprim, ampicillin, amoxicillin, quinolones, pyridines, and other major antibiotics	[67,68]
15.	**Carbonic anhydrase antagonist**	Acetazolamide, topiramate	[69,70]

Unique contemplations in pregnant women

Pregnant ladies are two times as prone to have calcium phosphate stones contrasted and age-matched non pregnant ladies, and some time adhere with calcium phosphate stones than oxalate stones.[71] There is a great risk of intense pain due to kidney stone in during the second and third trimesters. Ladies have an expanded glomerular filtration rate and higher urinary calcium discharge all through pregnancy, with higher pee pH in the second and third trimesters, which might incline them to calcium phosphate stones. For the imaging methodology, Ultrasonography is the technique that has been performed in pregnant ladies. Kidney stones during pregnancy increment the danger of urinary lot diseases, and pregnant ladies with renal colic have almost twofold the danger of pre-term conveyance contrasted and ladies who don't have kidney stones.[72]

CONCLUSION & FUTURE SCOPE

From this review, we conclude that it is the life threatening and systemic disease that affects all across the globe due to many factors. This disorder effectively affects the kidney dysfunction and posses several kind of complications and hence, leads to end stage renal disease. There are several etiological factors that promote the disease such as high oxalate consumption, increased supersaturation of urine, pathological condition of patient, intake of medications that enhanced the level of oxalate. There are several medications that are associated with the induction of kidney stone such as Ceftriaxone. Exhaustively, pathogenesis of this disease is also known for the therapeutics of this disorder that are based upon the nucleation; transformation of dissolved salts into a solid crystal. There are several drugs that are utilizes in the management of this disorder such as Non steroidal anti-inflammatory drugs, xanthine oxidase inhibitors i.e. allopurinol, antibiotics, carbonic anhydrase inhibitors, and thiazide diuretics. Patient dealing with nephrolithiais must focuses on healthy diet that basically involves intake of fibers from vegetables, fruits, citrus fruit and intake of vegetable juice, fruit juice, and water. Less intake of fatty food, milk, less intake of Ca^{2++} food to reduce the risk of nephrotlithiasis.

REFERENCES

1. L. Giannossi, V. Summa, “A review of pathological bio-mineral analysis techniques and classification schemes,” An Introduction to the Study of Mineralogy, 2012.
2. M. López, B. Hoppe, “History, epidemiology and regional diversities of urolithiasis,” Pediatric nephrology (Berlin, Germany), Jan 2010.
3. V.K. Sigurjonsdottir, H.L. Runolfsdottir, O.S. Indridason, R. Palsson, V.O. Edvardsson, “Impact of nephrolithiasis on kidney function,” BMC nephrology, 8 Aug 2015.

4. Y. Lotan, J. Antonelli, I.B Jiménez, H. Gharbi, R. Herring, A. Beaver, A. Dennis, D.Von Merveldt, S. Carter, A. Cohen, J. Poindexter, O.W. Moe, M.S. Pearle, "The kidney stone and increased water intake trial in steel workers: results from a pilot study," Urolithiasis, Apr 2017.
5. N, Abate, M, Chandalia, J.R. Cabo-Chan AV, O.W. Moe, K. Sakhaee, "The metabolic syndrome and uric acid nephrolithiasis novel features of renal manifestation of insulin resistance," Kidney Internationalernational, Feb 2004.
6. V. K. Sigurjonsdottir, H. L.Runolfsdottir, O. S. Indridasonet., "Impact of nephrolithiasis on kidney function," BMC Nephrology, 2015; 16(1): 149.
7. K. Mikawlrawng, S. Kumar, R. Vandana, "Current scenario of urolithiasis and the use of medicinal plants as antiurolithiatic agents in Manipur (North East India): a review," International Journal of Herbal Medicine, 2014; 2(1): 1–12.
8. Z.M. El-Zoghby, J. C. Lieske, R. N. Foley, "Urolithiasisand the risk of ESRD," Clinical Journal of the American Society of Nephrology, 2012; 7(9): 1409–1415.
9. A.D. Rule, V. L. Roger, L. J. Melton, "Kidney stones associate with increased risk for myocardial infarction," Journal of the American Society of Nephrology, 2010; 21(10): 1641–1644.
10. E.M. Worcester, F. L. Coe, "Nephrolithiasis," Primary Care, 2008; 35(2): 369–391.
11. E.N. Taylor, M.J. Stampfer, G.C. Curhan, "Obesity weight gain and the risk of kidney stones," Journal of the American Medical Association, 2005; 293(4): 455–462.
12. M. Courbebaisse, C. Prot- Bertoye, J. Bertocchio, "Nephrolithiasis of adult: from mechanisms to preventive medical treatment," Revue Medical International, 2017; 38(1): 44–52.
13. K.K. Stamatelou, M.E. Francis, C.A. Jones, "Time trends in reported prevalence of kidney stones in the United States," Kidney International, 2003; 63(5): 1817–1823.
14. J.M. Soucie, M.J. Thun, R.J. Coates, "Demographic and geographic variability of kidney stones in the United States," Kidney International, 1994; 46(3): 893–899.
15. Y.H. Lee, W.C. Huang, J.Y. Tsai, "Epidemiological studies on the prevalence of upper urinary calculi in Taiwan," Urologia Internationalis, 2002; 68(3): 72–177.
16. M.R. Safarinejad, "Adult urolithiasis in a population based study in Iran prevalence incidence and associated risk factors," Urological Research, 2007; 35(2): 73–82.
17. C.D. Jr Scales, A.C. Smith, J.M. Hanley, "Prevalence of kidney stones in the United States," European Urology, 2012; 62(1): 160–165.
18. Trinchieri, F. Coppi, E. Montanari, "Increase in the prevalence of symptomatic upper urinary tract stones during the last ten years," European Urology, 2000; 37(11): 23–27.
19. Finlayson, S.R. Khan, R.L. Hackett, "Mechanisms of stone Formation an overview," Scanning Microscopy, 1984; 7(3): 1419.
20. S.R. Khan, "Calcium oxalate crystal interaction with renal epithelium mechanism of crystal adhesion and its impact on stone development," Urological Research, 1996; 23(9): 71.
21. J.M. Fasano, S.R. Khan, "Intra-tubular crystallization of calcium oxalate in the presence of membrane vesicles," Kidney International, 2001; 169.
22. Trinchieri, F. Ostini, R. Nespoli, "A prospective study of recurrence rate and risk factors for recurrence after a first renal stone," Journal of Urology, 1999; 162(1): 27–30.
23. F.L. Levy, B. Adams-Huet, C.Y. Pak, "Ambulatory evaluation of nephrolithiasis an update of a 1980 protocol," The American Journal of Medicine, 1998; 98(1): 46–50.
24. C.Y. Pak, F. Britton, R. Peterson, "Ambulatory evaluation of nephrolithiasis Classification, clinical presentation and diagnostic criteria," The American Journal of Medicine, 1980; 69(1): 19–30.
25. S.R. Khan, M.S. Pearle, W.G. Robertson, "Kidney stones," Nature Reviews Disease Primers, 2016; 25(2): 16008.
26. E.M. Worcester, "Inhibitors of stone formation," Semin Nephrol, 1996; 16: 474-486.
27. O.W. Moe, "Kidney stones pathophysiology and medical crystals, 2006; 367: 9507: 333.
28. M.J. Chung, "Urolithiasis and nephrolithiasis," Journal of American Academy of Physician Assistant, Sep 2017; 30(9): 49-50.
29. R. Caudarella, F. Vescini, "Urinary citrate and renal stone disease: the preventive role of alkali citrate treatment," Archivio Italian Urologic Andrologia, Sep 2009; 81(3): 182-7.
30. G.C. Curhan, W.C. Willett, E.B. Rimm, M.J. Stampfer, "Family history and risk of kidney stones," Journal of American Society Nephrology, Oct 1997; 10(8): 1568-73.
31. P.M. Espino-Grosso, B.K. Canales, "Kidney Stones after Bariatric Surgery Risk Assessment and Mitigation," Bariatric Surgical Practice Patient Care, Mar 2017; 12(1): 3-9, 01.
32. E.N. Taylor, M.J. Stampfer, G.C. Curhan, "Obesity, weight gain, and the risk of kidney stones," Journal of American Medical Association, 26 Jan 2005; 293(4): 455-62.
33. D. Aune, Y. Mahamat-Saleh, T. Norat, E. Riboli, "Body fatness, diabetes, physical activity and risk of kidney stones a systematic review and meta-analysis of cohort studies," European Journal of Epidermal, Nov 2018; 33(11): 1033-1047.
34. D.L. Gentle, M.L. Stoller, T.W. Jarrett, J.F. Ward, K.S. Geib, A.F. Wood, "Protease inhibitor-induced urolithiasis," Urology, Oct 1997; 50(4): 508-11.
35. H. Izzedine, F.X. Lescure, F. Bonnet, "HIV medication-based urolithiasis," Clinical Kidney Journal, Apr 2014; 7(2): 121-6.

36. E. Parkhomenko, A. De Fazio, T. Tran, J. Thai, K. Blum, M. A. Gupta, "Multi-Institutional Study of Struvite Stones, Patterns of Infection and Colonization," Journal of Endourology, May 2017; 31(5): 533-537.
37. Q. Ma, L. Fang, R. Su, L. Ma, G. Xie, Y. Cheng, "Uric acid stones, clinical manifestations and therapeutic considerations," Postgraduate Medical Journal, Aug 2018; 94: 1114-458-462.
38. "Tolerable upper intake levels, "Calcium and vitamin D," In Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, 2011; 403–56.
39. G.C. Curhan, W.C. Willett, E.B. Rimm, D. Spiegelman, M.J. Stampfer, "Prospective study of beverage use and the risk of kidney stones," American Journal of Epidemiology, 1996; 143(3): 240–7.
40. S.M. Lewis, "Medical-surgical nursing assessment and manacrystalent of clinical problems", 2017.
41. R.V. Thakur, "Pathogenesis of Dent's disease and related syndromes of X-linked nephrolithiasis, Kidney International, March 2000; 57(3): 787–93.
42. National Endocrine and Metabolic Diseases Information Service, "Hyperparathyroidism Information about Endocrine and Metabolic Diseases A-Z list of Topics and Titles," Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Public Health Service, US Department of Health and Human Services, 2006.
43. B. Hoppe, C.B. Langman, "A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria," Pediatric Nephrology, 18(10): 986–91.
44. R.F. Reilly, Ch. 13 "Nephrolithiasis" In Reilly Jr & Perazella, 2005; 192–207.
45. National Kidney and Urologic Diseases Information Clearinghouse, "Modularly Sponge Kidney, Kidney & Urologic Diseases: A-Z list of Topics and Titles". Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Public Health Service, US Department of Health and Human Services, 2008.
46. J. Knight, D.G. Asimov, L. Easter, R.P. Holmes "Metabolism of fructose to oxalate and glycol ate," Hormone and Metabolic Research, Nov 2010; 42(12): 868.
47. National Digestive Diseases Information Clearinghouse, "Crohn's Disease, Digestive Diseases: A-Z List of Topics and Titles," Bethesda, Maryland National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, United States Public Health Service, United States Department of Health and Human Services, 2006.
48. G.M. Preminger, "Stone in the urinary tract the merck manual of medical information," 3rd edition, 2007.
49. R.F. Reilly, Ch. 13 "Nephrolithiasis," In Reilly Jr & Perazella, 2005; 192–207.
50. M. Cavendish, "Renal diseases Diseases and Disorders," Vol. 2 (1st edition), Tarrytown, New York, Marshall Cavendish Corporation, 2008; 490–3.
51. N. Mandel, "Mechanism of stone formation," Semin Nephrol, 1996; 16: 364-74.
52. J.R. Asplin, J.H. Parks, F.L. Coe, "Dependence of upper limit of meta stability on super saturation in nephrolithiasis," Kidney International, 1997; 52: 1602-8.
a. Randall. Recent Advances in Knowledge Relating to the Formation, Recognition and Treatment of Kidney Calculi. Bulletin of New York Academy of Medicine, 1944; 20(84): 473.
53. M. Asselman, A. Verhulst, E.S. Van Ballegooijen, Hyaluronan is apically secreted and expressed by proliferating or regenerating renal tubular cells. Kidney International, 2005; 8310.
54. Parks JH, Coe FL. An increasing number of calcium oxalate stone events worsens treatment outcome. Kidney International, 1994; 1722.
55. A.P. Evan, "Physiopathology and etiology of stone formation in the kidney and the urinary tract," Pediatr Nephrol, 2010; 25: 831- 41.
56. F.L. Coe, A.P. Evan, E.M. Worcester, J.E. Lingeman, "Three pathways for human kidney stone formation," Urology Research, 2010; 38: 147-60.
57. A.P. Evan, F.L. Coe, J. E. Lingeman, "Renal crystal deposits and histopathology in patients with cystine stones," Kidney International, 2006; 69: 2227-35.
58. A.P. Evan, F.L. Coe, D. Gillen, J.E. Lingeman, "Renal intra tubular crystals and hyaluronan staining occur in stone formers with bypass surgery but not with idiopathic calcium oxalate stones," Anatomical Record (Hoboken), 2008; 291: 325-34.
59. P.K. Pietrow, M.E. Karellas, "Medical management of common urinary calculi," Am Family Physician, 2006; 7(1): 88.
60. T. Eggermann, A. Venghaus, K. Zerres, "Cystinuria: an in born cause of urolithiasis," Orphanet Journal of Rare Disease, 2012; 5(7): 19.
61. D. Scholz, P.O. Schwille, A. Sigel, "Double-blind study with thiazide in recurrent calcium lithiasis," Journal of Urology, 1982; 128: 903–7.
62. C.Y. Pak, R. Peterson, K. Sakhaee, C. Fuller, G. Preminger, J. Reisch, "Correction of hypocitraturia and prevention of stone formation by combined thiazide and potassium citrate therapy in thiazide-unresponsive hypercalciuric nephrolithiasis," The American Journal of Medicine, 1985; 79: 284–288.
63. M. Urivetzky, S. Braverman, J.A. Motola, A.D. Smith AD, "Absence of effect of allopurinol on oxalate excretion by stone patients on random and controlled diets," Journal of Urology, 1990; 144: 97–98.
64. R.G. Russell, N.B. Watts, F.H. Ebetino, M.J. Rogers, "Mechanisms of action of bisphosphonates: similarities and differences and their potential

influence on clinical efficacy," Osteoporos International, 2008; 19: 733–759.
65. F. Sörgel, B. Ettinger, L.Z. Benet, "The true composition of kidney stones passed during triamterene therapy," Journal of Urology, 1985; 134(5): 871–873.
66. N. Chopra, P.L. Fine, B. Price, I. Atlas, "Bilateral hydronephrosis from ciprofloxacin induced crystaluria and stone formation," Journal of Urology, 2000; 164(2): 438.
67. W.H. Siegel, "Unusual complication of therapy with sulfamethoxazole trimethoprim," Journal of Urology, 1977; 117(3): 397.
68. S.P. Sterrett, K.L. Penniston, J.R. Wolf JS, S.Y. Nakada, "Acetazolamide is an effective adjunct for urinary alkalization in patients with uric acid and cystine stone formation recalcitrant to potassium citrate," Urology, 2008; 72(2): 278–281.
69. B.J. Welch, D. Gray beal, O.W. Moe, N.M. Maalouf, K. Sakhaee, "Biochemical and stone-risk profiles with topiramate treatment," American Journal of Kidney Disease, 2006; 48(4): 555–563.
70. A.E. Ross, S. Handa, J.E. Lingeman, B.R. Matlaga, "Kidney stones during pregnancy an investigation into stone composition," Urology Research, 2008; 36(2): 99–102.
71. M.A. Swartz, M.T. Lydon-Rochelle, D. Simon, J.L. Wright, M.P. Porter, "Admission for nephrolithiasis in pregnancy and risk of adverse birth outcomes," obstetrics and gynecology, 2007; 109(5): 1099–1104.